You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results

Citation Tools

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Suh C, Khouri ECE, Miranda P, et al
SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results
Annals of the Rheumatic Diseases 2017;76:824-825.